ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0812

COVID-19 Short-Term Outcomes of AKI and Chronic Hemodialysis

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Smolander, Jessica, Danderyds Sjukhus AB, Stockholm, Sweden
  • Bruchfeld, Annette, Karolinska Universitetssjukhuset, Stockholm, Sweden

Acute kidney injury (AKI), albuminuria and hematuria are common and increase mortality in Covid-19 in addition to viral pneumonia, hypercoagulability and hyperinflammation. We present short-term outcomes of 21 Covid-19 patients with AKI and CRRT and the clinical course of 40 chronic hemodialysis (HD) patients with Covid-19.

Case Description

Twenty-one non-CKD Covid-19 infected patients with AKI required mechanical ventilation and CRRT at the ICU, 20 were males, average age was 59.7 years (y), average BMI 29 kg/m2, 33 % had diabetes. The typical scenario was a normal/slightly elevated creatinine level at admission, normalizing after iv fluids, but rising creatinine from day 3-4 and start of CRRT on day 8 (median). Urine analysis was available in eight patients, of which seven had albuminuria and/or hematuria. So far eight patients (38 %) have died. Dialysis has been discontinued in nine patients (43 %), median time 17 days in dialysis (range 1-35 days), follow up of 1-4 weeks. Patients 3-4 weeks after CRRT discontinuation have a creatinine level of 50-161 μmol/L (ref < 90-100 μmol/L). Four patients are still dialysis dependent (median time in dialysis 7-22 days).
Forty out of 520 patients on chronic HD in Stockholm had symptomatic Covid-19 in March-April 2020, of these 24 patients (60 %) required hospitalization, 16 patients (40%) did not. Nine patients died (22,5 %), of whom eight were men. The average age (78 y) was significantly higher (p = 0.003) and median time in dialysis (11.5 y) was longer (p = 0.01) in the non-survivors compared to the survivors. CRP at admission was significantly higher in the non-survivors (p=0.0003), but there were no differences regarding prior cardiovascular disease or diabetes (56 vs 55 %). Only three patients had a BMI > 30 kg/m2. Among survivors, the number of patients with ACE inhibitor/ARB treatment did not differ from non-survivors (p = 0.08), 13 out of 15 patients continued their treatment, without more serious disease.


The AKI mortality in Covid-19 with CRRT is high, but a substantial number of patients have survived and recovered kidney function although follow-up for long-term CKD prognosis is important. Fewer chronic HD patients than expected suffered severe disease, however patients older than 70 y in combination with longer time (> 10 y) in HD and high CRP at admission were at a higher risk of dying from symptomatic Covid-19.